Skip to content
Disclosery

EXANE DERIVATIVES: KBE position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on KBE, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 2 KBE shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 2 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $88.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 2 shares
    Change vs previous 13F -26,093 shares

    <0.01% of the 13F portfolio, value $105.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 26,095 shares
    Change vs previous 13F +14,712 shares

    0.35% of the 13F portfolio, value $1,423,692.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 11,383 shares
    Change vs previous 13F -10,534 shares

    0.15% of the 13F portfolio, value $602,253.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 21,917 shares
    Change vs previous 13F +5,362 shares

    0.26% of the 13F portfolio, value $1,092,537.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 16,555 shares
    Change vs previous 13F not available

    0.26% of the 13F portfolio, value $858,835.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).